CHAMPIONS ONCOLOGY INC (CSBR) Stock Fundamental Analysis
NASDAQ:CSBR - Nasdaq - US15870P3073 - Common Stock - Currency: USD
CSBR gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 56 industry peers in the Life Sciences Tools & Services industry. While CSBR is still in line with the averages on profitability rating, there are concerns on its financial health. CSBR has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
CSBR had positive earnings in the past year.
CSBR had a negative operating cash flow in the past year.
In multiple years CSBR reported negative net income over the last 5 years.
The reported operating cash flow has been mixed in the past 5 years: CSBR reported negative operating cash flow in multiple years.
1.2 Ratios
Looking at the Return On Assets, with a value of 20.98%, CSBR belongs to the top of the industry, outperforming 96.43% of the companies in the same industry.
CSBR has a Return On Equity of 117.52%. This is amongst the best in the industry. CSBR outperforms 100.00% of its industry peers.
With an excellent Return On Invested Capital value of 49.38%, CSBR belongs to the best of the industry, outperforming 98.21% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 20.98% | ||
| ROE | 117.52% | ||
| ROIC | 49.38% |
ROA(3y)-13.95%
ROA(5y)-10.02%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With an excellent Profit Margin value of 10.97%, CSBR belongs to the best of the industry, outperforming 85.71% of the companies in the same industry.
CSBR has a Operating Margin of 11.48%. This is in the better half of the industry: CSBR outperforms 66.07% of its industry peers.
The Gross Margin of CSBR (51.58%) is comparable to the rest of the industry.
CSBR's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 11.48% | ||
| PM (TTM) | 10.97% | ||
| GM | 51.58% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.65%
GM growth 5Y-2.63%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), CSBR is creating value.
The number of shares outstanding for CSBR has been increased compared to 1 year ago.
CSBR has more shares outstanding than it did 5 years ago.
There is no outstanding debt for CSBR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
Based on the Altman-Z score of 1.17, we must say that CSBR is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 1.17, CSBR is in line with its industry, outperforming 42.86% of the companies in the same industry.
A Debt/Equity ratio of 0.02 indicates that CSBR is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.02, CSBR is in the better half of the industry, outperforming 67.86% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.02 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 1.17 |
ROIC/WACC4.84
WACC10.2%
2.3 Liquidity
CSBR has a Current Ratio of 0.99. This is a bad value and indicates that CSBR is not financially healthy enough and could expect problems in meeting its short term obligations.
The Current ratio of CSBR (0.99) is worse than 87.50% of its industry peers.
A Quick Ratio of 0.99 indicates that CSBR may have some problems paying its short term obligations.
CSBR has a Quick ratio of 0.99. This is amonst the worse of the industry: CSBR underperforms 80.36% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.99 | ||
| Quick Ratio | 0.99 |
3. Growth
3.1 Past
CSBR shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 176.81%, which is quite impressive.
The Revenue has grown by 19.03% in the past year. This is quite good.
The Revenue has been growing by 13.13% on average over the past years. This is quite good.
EPS 1Y (TTM)176.81%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%325%
Revenue 1Y (TTM)19.03%
Revenue growth 3Y6.91%
Revenue growth 5Y13.13%
Sales Q2Q%41.77%
3.2 Future
The Earnings Per Share is expected to grow by 56.78% on average over the next years. This is a very strong growth
Based on estimates for the next years, CSBR will show a quite strong growth in Revenue. The Revenue will grow by 17.84% on average per year.
EPS Next Y162.45%
EPS Next 2Y56.78%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year15.88%
Revenue Next 2Y11.77%
Revenue Next 3Y17.89%
Revenue Next 5Y17.84%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
CSBR is valuated reasonably with a Price/Earnings ratio of 11.43.
Compared to the rest of the industry, the Price/Earnings ratio of CSBR indicates a rather cheap valuation: CSBR is cheaper than 94.64% of the companies listed in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 27.75, CSBR is valued rather cheaply.
The Price/Forward Earnings ratio is 27.01, which means the current valuation is very expensive for CSBR.
Based on the Price/Forward Earnings ratio, CSBR is valued a bit cheaper than 62.50% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 20.49. CSBR is valued slightly more expensive when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 11.43 | ||
| Fwd PE | 27.01 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, CSBR is valued cheaper than 96.43% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 10.12 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
CSBR's earnings are expected to grow with 56.78% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.07
PEG (5Y)N/A
EPS Next 2Y56.78%
EPS Next 3YN/A
5. Dividend
5.1 Amount
No dividends for CSBR!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:CSBR (5/2/2025, 10:46:56 AM)
6.06
-0.32 (-5.02%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners47.82%
Inst Owner Change0%
Ins Owners25.86%
Ins Owner Change2.28%
Market Cap83.81M
Analysts82.86
Price Target12.24 (101.98%)
Short Float %1.42%
Short Ratio3.64
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)2009.8%
Min EPS beat(2)390.2%
Max EPS beat(2)3629.41%
EPS beat(4)4
Avg EPS beat(4)1146.3%
Min EPS beat(4)106.13%
Max EPS beat(4)3629.41%
EPS beat(8)5
Avg EPS beat(8)540.78%
EPS beat(12)6
Avg EPS beat(12)292.36%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)15.24%
Min Revenue beat(2)1.31%
Max Revenue beat(2)29.17%
Revenue beat(4)4
Avg Revenue beat(4)10.71%
Min Revenue beat(4)1.31%
Max Revenue beat(4)29.17%
Revenue beat(8)4
Avg Revenue beat(8)1.57%
Revenue beat(12)6
Avg Revenue beat(12)0.9%
Revenue beat(16)10
Avg Revenue beat(16)1.14%
PT rev (1m)0%
PT rev (3m)50%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-1100%
EPS NY rev (1m)0%
EPS NY rev (3m)42.86%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-12.18%
Revenue NY rev (1m)0.8%
Revenue NY rev (3m)0.8%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 11.43 | ||
| Fwd PE | 27.01 | ||
| P/S | 1.43 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 15.32 | ||
| P/tB | 16.32 | ||
| EV/EBITDA | 10.12 |
EPS(TTM)0.53
EY8.75%
EPS(NY)0.22
Fwd EY3.7%
FCF(TTM)-0.1
FCFYN/A
OCF(TTM)-0.09
OCFYN/A
SpS4.24
BVpS0.4
TBVpS0.37
PEG (NY)0.07
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 20.98% | ||
| ROE | 117.52% | ||
| ROCE | 62.51% | ||
| ROIC | 49.38% | ||
| ROICexc | 70.31% | ||
| ROICexgc | 73.57% | ||
| OM | 11.48% | ||
| PM (TTM) | 10.97% | ||
| GM | 51.58% | ||
| FCFM | N/A |
ROA(3y)-13.95%
ROA(5y)-10.02%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.65%
GM growth 5Y-2.63%
F-Score5
Asset Turnover1.91
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.02 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 0.01 | ||
| Cap/Depr | 1.47% | ||
| Cap/Sales | 0.04% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.99 | ||
| Quick Ratio | 0.99 | ||
| Altman-Z | 1.17 |
F-Score5
WACC10.2%
ROIC/WACC4.84
Cap/Depr(3y)106.12%
Cap/Depr(5y)172.76%
Cap/Sales(3y)3.95%
Cap/Sales(5y)5.35%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)176.81%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%325%
EPS Next Y162.45%
EPS Next 2Y56.78%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)19.03%
Revenue growth 3Y6.91%
Revenue growth 5Y13.13%
Sales Q2Q%41.77%
Revenue Next Year15.88%
Revenue Next 2Y11.77%
Revenue Next 3Y17.89%
Revenue Next 5Y17.84%
EBIT growth 1Y176.48%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year162.59%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-146.42%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-123.77%
OCF growth 3YN/A
OCF growth 5YN/A